Abstract:The norepinephrine transporter (NET), encoded by the SLC6A2 gene, is one of three key monoamine neurotransmitter transporters. Inhibition of NET-mediated reuptake of norepinephrine by monoamine reuptake inhibitors has been the main therapeutic strategy to treat disorders such as depression, ADHD and Parkinson's disease. Nevertheless, lack of efficacy as well as risk of adverse effects are still common for these treatments underscoring the necessity to improve drug discovery efforts for this target. In this study, we developed new inhibitors based on 4-((2-(3,4-dichlorophenyl)cyclopentyl)amino)butan-1-ol (8), a potent NET inhibitor, which emerged from earlier virtual screening efforts using a predictive proteochemometric model. Hence, we optimized the N,2-substituted cycloalkylamine scaffold in three regions to design twenty new derivatives. To establish structure-activity relationships for these NET inhibitors, all novel compounds were tested utilizing an impedance-based 'transporter activity through receptor activation' assay. Moreover, all stereoisomers of the most potent compound (27) were synthesized and evaluated for their inhibitory potencies. Initial screening indicated that modifications in the cyclopentylamine moiety and phenyl substitutions decreased NET inhibition compared to 8, emphasizing the importance of the five-membered ring, secondary amine and dichloro-substitution pattern in NET binding. Substituting the original butylalcohol at the R 2 position with a rigid cyclohexanol yielded lead compound 27, with potency similar to reference inhibitor nisoxetine. Pharmacological characterization of all eight stereoisomers of 27 revealed varying inhibitory potencies, favoring a trans-orientation of the N,2-substituted cyclopentyl moiety. Molecular docking highlighted key interactions and the impact of a hydrophilic region in the binding pocket. This study presents a novel set of moderate to highly potent NET inhibitors, elucidating the influence of molecular orientation in the NET binding pocket and offering valuable insights into drug discovery efforts for monoamine transport-related treatments.

Structural Models of Human Norepinephrine Transporter Ensemble Reveal the Allosteric Sites and Ligand-Binding Mechanism

Molecular basis of human noradrenaline transporter reuptake and inhibition

Transport and inhibition mechanisms of the human noradrenaline transporter

Substrate binding and inhibition mechanism of norepinephrine transporter

Structural Mechanisms of Human Sodium-Coupled High-Affinity Choline Transporter CHT1

Mechanistic insights of substrate transport and inhibitor binding revealed by high-resolution structures of human norepinephrine transporter

Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study

Substrate-induced Conformational Dynamics of the Dopamine Transporter

Stereochemical optimization of N,2-substituted cycloalkylamines as norepinephrine reuptake inhibitors

Dimerization and antidepressant recognition at noradrenaline transporter

Cryo-EM structure of the human NKCC1 transporter reveals mechanisms of ion coupling and specificity

Conformational Transitions of a Neurotensin Receptor 1–G I1 Complex

Oligomerization of Monoamine Transporters

The structural basis of function and regulation of neuronal cotransporters NKCC1 and KCC2

Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket

Computational Characterization of the Selective Inhibition of Human Norepinephrine and Serotonin Transporters by an Escitalopram Scaffold

Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters.

Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

Understanding The Polypharmacological Profiles Of Triple Reuptake Inhibitors By Molecular Simulation

Alternating Access of a Neurotransmitter:Sodium Symporter Bacterial Homolog Determined from AlphaFold2 Ensembles and DEER Spectroscopy

Structural bioinformatics studies of serotonin, dopamine and norepinephrine transporters and their AlphaFold2 predicted water-soluble QTY variants and uncovering the natural mutations of L->Q, I->T, F->Y and Q->L, T->I and Y->F